MedTrace Logo

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

NCT00798590 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-07-02

Study results available
· View outcomes & findings →

Summary

The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.

Conditions

Interventions

DRUG

Glucagon-Like Peptide-1

5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.

DRUG

Saline

5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.

Sponsors & Collaborators

Principal Investigators

  • Dariush Elahi, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00798590 on ClinicalTrials.gov